GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » Cyclically Adjusted PB Ratio

Athersys (FRA:4LSA) Cyclically Adjusted PB Ratio : (As of May. 29, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Athersys Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Athersys Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Athersys's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Cyclically Adjusted PB Ratio Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.06 3.51 5.93 3.37 0.13

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.13 0.20 0.14 0.07

Competitive Comparison of Athersys's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Athersys's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athersys's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Athersys's Cyclically Adjusted PB Ratio falls into.



Athersys Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Athersys's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Athersys's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-1.562/129.8595*129.8595
=-1.562

Current CPI (Sep. 2023) = 129.8595.

Athersys Quarterly Data

Book Value per Share CPI Adj_Book
201312 5.118 98.326 6.759
201403 6.958 99.695 9.063
201406 7.355 100.560 9.498
201409 6.712 100.428 8.679
201412 5.452 99.070 7.146
201503 5.363 99.621 6.991
201506 5.731 100.684 7.392
201509 4.146 100.392 5.363
201512 5.407 99.792 7.036
201603 6.790 100.470 8.776
201606 5.200 101.688 6.641
201609 4.175 101.861 5.323
201612 3.059 101.863 3.900
201703 6.135 102.862 7.745
201706 5.120 103.349 6.433
201709 4.679 104.136 5.835
201712 4.045 104.011 5.050
201803 6.985 105.290 8.615
201806 8.686 106.317 10.609
201809 7.690 106.507 9.376
201812 6.566 105.998 8.044
201903 5.489 107.251 6.646
201906 4.847 108.070 5.824
201909 3.948 108.329 4.733
201912 3.277 108.420 3.925
202003 2.518 108.902 3.003
202006 7.232 108.767 8.634
202009 4.744 109.815 5.610
202012 3.191 109.897 3.771
202103 3.733 111.754 4.338
202106 2.847 114.631 3.225
202109 2.651 115.734 2.975
202112 1.491 117.630 1.646
202203 0.028 121.301 0.030
202206 -1.009 125.017 -1.048
202209 -1.297 125.227 -1.345
202212 -1.252 125.222 -1.298
202303 -1.570 127.348 -1.601
202306 -1.582 128.729 -1.596
202309 -1.562 129.860 -1.562

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Athersys  (FRA:4LSA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Athersys Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Athersys's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (FRA:4LSA) Business Description

Industry
Traded in Other Exchanges
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Athersys (FRA:4LSA) Headlines

No Headlines